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Ascorbic acidAlthough ascorbate has long been known to stimulate dietary iron (Fe) absorption and non-transferrin Fe
uptake, the role of ascorbate in transferrin Fe uptake is unknown. Transferrin is a serum Fe transport protein sup-
plying almost all cellular Fe under physiological conditions. We sought to examine ascorbate's role in this pro-
cess, particularly as cultured cells are typically ascorbate-deﬁcient. At typical plasma concentrations, ascorbate
signiﬁcantly increased 59Fe uptake from transferrin by 1.5–2-fold in a range of cells. Moreover, ascorbate
enhanced ferritin expression and increased 59Fe accumulation in ferritin. The lack of effect of cycloheximide or
the cytosolic aconitase inhibitor, oxalomalate, on ascorbate-mediated 59Fe uptake from transferrin indicate
increased ferritin synthesis or cytosolic aconitase activity was not responsible for ascorbate's activity. Experi-
ments withmembrane-permeant and -impermeant ascorbate-oxidizing reagents indicate that while extracellu-
lar ascorbate is required for stimulation of 59Fe uptake from 59Fe-citrate, only intracellular ascorbate is needed for
transferrin 59Fe uptake. Additionally, experiments with L-ascorbate analogs indicate ascorbate's reducing
ene-diol moiety is necessary for its stimulatory activity. Importantly, neither N-acetylcysteine nor buthionine
sulfoximine, which increase or decrease intracellular glutathione, respectively, affected transferrin-dependent
59Fe uptake. Thus, ascorbate's stimulatory effect is not due to a general increase in cellular reducing capacity.
Ascorbate also did not affect expression of transferrin receptor 1 or 125I-transferrin cellular ﬂux. However, trans-
ferrin receptors, endocytosis, vacuolar-type ATPase activity and endosomal acidiﬁcation were required for
ascorbate's stimulatory activity. Therefore, ascorbate is a novel modulator of the classical transferrin Fe uptake
pathway, acting via an intracellular reductive mechanism.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Vitamin C (L-ascorbate) is typically abundant within vertebrate cells
and in extracellular ﬂuids and functions as a one-electron reductant
[1,2]. Unlike most animals, a small proportion of vertebrate species (in-
cluding humans and other haplorhine primates) are incapable of the syn-
thesis of L-ascorbate and develop scurvy if deprived of the vitamin [1].
Mammalian cells import ascorbate via: (i) sodium-dependent ascorbateanthroline disulfonate; BSA, bo-
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rights reserved.transporters (SVCTs) [3]; and/or (ii) as the oxidized form of ascorbate,
dehydroascorbate (DHA), by facilitative glucose transporters (GLUTs).
In the latter case, DHA is reduced intracellularly to ascorbate by
NAD(P)H- and reduced glutathione (GSH)-dependent recycling path-
ways [4–7].
Cultured mammalian cells are generally devoid of ascorbate for 3
reasons: (i) most mammalian cells, even those from ascorbate-
synthesizing species, do not synthesize appreciable levels of ascorbate
in culture [1,4,5]; (ii) the vitamin rapidly and irreversibly degrades
under culture conditions [8]; and (iii) cultured cells are typically not
supplementedwith ascorbate [6]. Thus,manyprevious studies performed
in vitro to assess basic metabolic processes have lacked a crucial vitamin
that is typically abundant in vivo.
Iron (Fe) is an essential element, being vital for a wide variety of
metabolic processes [9]. It has long been known that ascorbate deﬁ-
ciency leads to anemia and other symptoms typical of scurvy
[10–12]. In experimentally-induced scurvy [10,12] and in most clin-
ical cases [11,13–15], ascorbate is required to correct this anemia. Addi-
tionally, orally administered ascorbate has amarked beneﬁcial effect on
hematologic parameters in anemic hemodialysis patients [16]. Howev-
er, the mechanisms by which ascorbate elicits these effects are unclear.
Ascorbate enhances dietary non-heme Fe absorption [17,18], which
is typically thought to be themajor role of the vitamin in Femetabolism
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Fe uptake from low-Mr Fe-citrate complexes [4,19,20]. Such observa-
tions suggest that the function of ascorbate in Femetabolism is complex
[17].
Once dietary Fe is absorbed and released into the bloodstream,
virtually all of the metal is bound to the Fe-transport protein, trans-
ferrin (Tf) from which it is distributed to all other tissues throughout
the body. Strikingly, the role of ascorbate in Tf-bound Fe uptake is
unknown. Indeed, although scurvy is associated with a form of
Fe-deﬁciency anemia [10–15], the mechanism responsible has not
been determined. Tf binds two atoms of Fe(III) to form di-ferric
Tf (Fe2-Tf), which is delivered to cells after the binding of Fe2-Tf to
the Tf receptor 1 (TfR1) [21,22]. This complex is internalized by
receptor-mediated endocytosis, followed by a vacuolar-type H+-ATPase
(V-ATPase)-dependent decrease in endosomal pH that destabilizes the
binding of Fe to Tf [21,23,24]. The Fe(III) must then reduced to Fe(II)
prior to its release from the endosome into the cytoplasm via divalent
metal transporter 1 (DMT1; Nramp2) [25] and/or analogous Fe(II) trans-
porters such as Zip14 [26]. Once in the cytoplasm, this Fe can enter the
labile Fe pool (LIP) [27], which may consist of Fe-chaperone proteins
that supply Fe to Fe-containing proteins and/or provide Fe for storage
in ferritin [28].
Importantly, a potentially rate-limiting step in the cellular acquisition
of Fe by the Tf-to-cell cycle is the reduction of intra-endosomal Fe, which
depends on an incompletely understood endosomal ferrireductase activ-
ity [29]. Although a candidate ferrireductase in erythroid cells is the ‘six
transmembrane epithelial antigen of the prostate, isoform 3’ (Steap3),
Steap3−/− mice still have 60% of the hemoglobin levels of wild-type
mice [30]. This indicates that mammalian cells in vivo possess other
means of reducing intra-endosomal Fe.
In this study, we examined the role of ascorbate on the cellular
uptake of Fe from Fe2-Tf. For the ﬁrst time, we demonstrate that physi-
ological concentrations of ascorbate signiﬁcantly increase Tf-dependent
Fe uptake by a range of human cells. Signiﬁcantly, the mechanism of
ascorbate-stimulated Fe uptake from Fe2-Tf is different to that involved
in the ascorbate-stimulated uptake of low-Mr Fe. Indeed, the mecha-
nism involved requires: (i) the reductive action of intracellular, but
not extracellular ascorbate; (ii) the expression of functional TfRs 1
(or 2), but not changes in cellular Tf uptake/ release or changes in
TfR1 expression; and (iii) endocytosis and endosomal acidiﬁcation.
Our data suggest that ascorbate acts via a reductive mechanism involv-
ing the enhancement of endosomal ferrireduction.
2. Materials and methods
2.1. Reagents
Unless stated, all chemicals were purchased from Sigma-Aldrich
(St. Louis, MO). The following radio-nuclides were purchased from
PerkinElmer (Waltham, MA): [59Fe]Cl3 (Cat. #: NEZ037) and Na125I
(Cat. #: NEZ033A). Oxalomalic acid (sodium salt; Cat. #: 13521) and
the following metalloporphyrins were purchased from Cayman Chemi-
cal Co. (Ann Arbor, MI, USA): Mn(III)tetrakis(4-benzoic acid) porphyrin
chloride (MnTBAP; Cat. #: 75850), Mn(III)tetrakis(1-methyl-4-pyridyl)
porphyrin pentachloride (MnTMPyP; Cat. #: 75852) and Fe(III)
tetrakis(1-methyl-4-pyridyl)porphyrin pentachloride (FeTMPyP; Cat.
#: 75854).
2.2. Cell culture
The human cell lines: melanoma: SK-Mel-28, SK-Mel-2, SK-Mel-5
and VMM12; hepatocellular carcinoma: HepG2; neuroepithelioma:
SK-N-MC; chronic myelogenous leukemia: K562 (American Type Culture
Collection, Manassas, VA); and primary cultures of human umbilical
vein endothelial cells (HUVECs; obtained from Mr. Pat Pisansarakit,
Heart Research Institute, Sydney, Australia) were grown as described[31]. Variant Chinese hamster ovary (CHO-TRVb) cells, which are devoid
of endogenous TfRs [32], were grown in MEM supplemented with 10%
(v/v) FBS, L-glutamine (2 mM), penicillin (100 U/mL), streptomycin
(100 μg/mL), sodium pyruvate (1 mM) and 1× non-essential amino
acids (Gibco; Invitrogen: Mulgrave, VIC, Australia). The CHO-TRVb
cells stably transfected to express human TfR1 (TRVb/TfR1) [32], or
CHO-TRVb cells transfected with FLAG-tagged human TfR2-α (TRVb/
TfR2) [33,34], or the TfR2-α vector (i.e., pcDNA3-FLAG), which imparts
neomycin/G418-resistance [33,34] (TRVb/Neo), were grown in themedi-
umdescribed above supplementedwith G418 sulfate (200 μg/mL; G418)
[33,34]. All CHO-TRVb cell lines were provided by Drs. R. Graham and D.
Trinder, Fremantle Hospital, Perth, Western Australia, with the permis-
sion of T. McGraw (Weill Cornell Medical College), H. Kawabata (Kyoto
University, Japan) and H.P. Koefﬂer (University of California).
2.3. Determination of intracellular ascorbate
Intracellular ascorbate levels were determined either as described
previously [4] or by the Tempol-dependent oxidation of ascorbate to
DHA followed by condensation of DHA with o-phenylenediamine to
form a ﬂuorescent product [35]. Both methods provided identical
results.
2.4. Determination of intracellular total NADP and NADPH levels
Intracellular total NADP and NADPH levels were determined using
a kit from Abcam (Cambridge, MA).
2.5. Preparation of 59Fe-125I-Transferrin
Human apo-Tf (Sigma-Aldrich) was labeled with [59Fe] or non-
radioactive Fe to produce the 59Fe- or Fe-labeled di-ferric proteins,
respectively [36]. In some experiments, 59Fe2-Tf or Fe2-Tf were also
labeled with 125I [36,37].
2.6. Effect of ascorbate on 59Fe2-
125I-Tf Uptake by Cells
The effect of ascorbate on cellular 59Fe uptake from 59Fe2-125I-Tf was
examined using established techniques [36,38]. Brieﬂy, cells were pre-
incubated with or without ascorbate (10–500 μM) for 5–60 min/37 °C
before the addition of 59Fe2-Tf or 59Fe2\125I-Tf (0.75 μM; [Fe] =
1.5 μM) or 59Fe-citrate ([Fe] = 1.5 μM; molar ratio or Fe to citrate =
1:100) to the same medium for 3 h/37 °C. In some experiments, DHA
(50 μM) was used in place of ascorbate. The cells were then washed
ﬁve times on ice with ice-cold PBS to remove non-speciﬁcally bound
59Fe2-Tf. Internalized 59Fe was determined by standard methods by
incubating cells on ice for 30 min/4 °C with the general protease,
“Pronase” (1 mg/mL) [23,36]. Cells were then detached following
Pronase treatment and centrifuged (16,000 g/4 °C/1 min) in an
Eppendorf microcentrifuge (Hamburg, Germany). The resulting super-
natant represents cell-surface (i.e., Pronase-sensitive; hereinafter
referred to as “cell membrane”) 59Fe and 125I that were released by
extracellular proteolysis, while the Pronase-insensitive fraction repre-
sents internalized 59Fe and 125I [23,36]. Radioactivity was quantitated
using a γ-counter (2480 Wizard2, Perkin Elmer, Turku, Finland).
In some experiments, the effect of ascorbate on the afﬁnity of
Fe2\125I-Tf binding and the total number of cell-surface Tf-receptors
was assessed by pre-incubating SK-Mel-28 cells with or without ascor-
bate (50 μM) for 30 min/37 °C, then cooling the cells to 4 °C and incu-
bating them for a further 2 h at 4 °C with increasing concentrations of
Fe2\125I-Tf (0.0125–1 μM). Cells were then washed and the amount
of speciﬁcally bound radioactivity was determined by subtracting the
amount of Fe2\125I-Tf bound in the presence of a 200-fold excess of
unlabeled Fe2-Tf. At 4 °C, endocytic internalization of the Fe2-Tf–TfR
complex is inhibited, but the ligand–receptor interaction is unaffected
[36].
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The effect of ascorbate on 59Fe and/or 125I-Tf efﬂux from cells
pre-labeled with 59Fe\125I-Tf was examined as previously described
[39]. Brieﬂy, cellswere incubatedwith 59Fe\125I-Tf (0.75 μM) for either
30 min or 3 h/37 °C. The cells were then placed on ice and washed ﬁve
times with ice-cold PBS and re-incubated with or without ascorbate
(50 μM) for 5–30 min or 3 h/37 °C. At the end of the incubation, the
overlying medium was aspirated into γ-counting tubes and the cell
mono-layers solubilized in 2% (w/v) SDS [20]. Levels of 59Fe or 125I-Tf
were determined as above.
2.8. SDS-PAGE and Western blotting
SDS-PAGE (reducing conditions), western blotting and densitome-
try were performed as described [40]. The following antibodies were
used to probe for speciﬁc proteins. Mouse monoclonal anti-human
TfR1 (clone H68.4) was from Invitrogen (Cat. #: 13-6800). Rabbit poly-
clonal anti-human TfR2 was from Abcam (Cat. #: ab83810). Rabbit
polyclonal anti-ferritin heavy chain (FTH1) was from Cell Signaling
Technology (Cat. #: 3998; Danvers, MA). Rabbit polyclonal anti-
ferritin light chain (FTL) was from Abcam (Cat. #: ab69090). Rabbit
polyclonal anti-Steap3 was from Abnova (Cat. #: PAB13008). Mouse
monoclonal anti-β-actin (clone AC-40; Cat. #: A4700) was from
Sigma-Aldrich. The secondary antibodies used (1:5000)were horserad-
ish peroxidase-conjugated anti-mouse (Cat. #: A9044) and anti-rabbit
(Cat. #: A0545) from Sigma-Aldrich.
Membranes were washed and developed using ECL + Western blot
detection reagent (AmershamBiosciences, Buckinhamshire, UK) and ex-
posed to X-ray ﬁlm. Densitometrywas performed using BioRad Quantity
One software (Hercules, CA). All data were normalized to the loading
control, β-actin. Chemiluminescent immunodetection by X-ray ﬁlm
yielded a linear signal output within 5% error over (i) the protein loading
levels employed, and (ii) the exposure time intervals examined. Thiswas
conﬁrmedusing a digital imaging BioRad ChemiDocMP system, showing
that exposures were within the linear range of the ﬁlm and that chemi-
luminescent substrate was not limiting.
2.9. Native PAGE-59Fe-autoradiography
Native PAGE-59Fe-autoradiography was performed using established
techniques [41]. Where noted, anti-ferritin “super-shifts” were used to
identify the location of endogenous ferritin by incubating cell extracts
(100 μg protein) with 10 μg of rabbit polyclonal anti-horse spleen
ferritin (Sigma-Aldrich; Cat. #: F6136) or rabbit polyclonal anti-human
ferritin (MP Biomedicals; Seven Hills, NSW, Australia; Cat. #: 65077)
for 1 h/4 °C. To control for possible non-speciﬁc effects of the antibody,
an equivalent amount of rabbit polyclonal anti-cyclin D1 (Abcam; Cat.
#: ab24249) was used, which had no effect on 59Fe distribution. The
location of the low-Mr 59Fe fraction was determined by the incubation
of cell extracts with 100 μM of the strong Fe chelator, desferrioxamine
(DFO; Novartis, Basel, Switzerland), for 1 h/4 °C [41]. The pre-
incubation of cell extracts with DFO binds and reproducibly removes
low-Mr 59Fe [41,42]. Importantly, the DFO-59Fe complex does not
appear in the gel due to the net positive charge of the complex at the
running pH, which leads to its migration in the opposite direction to
59Fe-ferritin and low-Mr 59Fe.
2.10. Statistical analysis
All statistical analyseswere performed usingGraphPadPrism®v. 5.0
(GraphPad Software, California). Means were compared using one-way
ANOVA with Bonferroni's post hoc test of signiﬁcance [4,7,20]. Results
are expressed as means ± SD (number of experiments) and were con-
sidered to be statistically signiﬁcant when p b 0.05.3. Results
3.1. The incubation of ascorbate-depleted cells with ascorbate or DHA
increases intracellular ascorbate
Typical human plasma ascorbate concentrations in unsupplemented
individuals are 40–60 μM [43]. Therefore, unless otherwise stated, cells
were incubated with or without ascorbate or ascorbate analogues
(50 μM) for 30 min/37 °C before the addition of 59Fe as 59Fe2-Tf to the
same medium for 3 h/37 °C (hereinafter referred to as the ‘standard
incubation protocol’). Unless supplemented with the vitamin (see
below), the cells used in this study were devoid of detectable ascorbate
(Table 1, column A). This observation is typical of mammalian cells
grown under standard culture conditions [4,7,8,19,20].
Importantly, incubation of SK-Mel-28 cells with ascorbate for
30 min or 3 h increased intracellular ascorbate fromundetectable levels
to 202–375 pmol/106 cells (Table 1). Incubation of these cells with
DHA (50 μM) for 30 min/37 °C, which is rapidly reduced to ascorbate
once imported by cells [6], increased their ascorbate content to
534 ± 19 pmol/106 cells (Table 1).
3.2. Ascorbate stimulates cellular 59Fe uptake from 59Fe2-Tf in human
cells
In initial studies, we used a wide range of human cells to examine
the effect of ascorbate on 59Fe uptake. Incubation of SK-Mel-28 cells
(Fig. 1) with ascorbate signiﬁcantly (p b 0.001) increased their inter-
nalized 59Fe uptake from 59Fe2-Tf by ~2-fold that of cells incubated in
the absence of ascorbate. While there was also a trend towards an
increase in cell-membrane 59Fe uptake, this represented a small propor-
tion (b10%) of total 59Fe uptake and was typically not signiﬁcant
(p > 0.05; Fig. 1). Under the same conditions, ascorbate also signiﬁcant-
ly (p b 0.001–0.01) stimulated internalized 59Fe uptake from 59Fe2-Tf in
all other human cells examined, including primary HUVECs, and all
other human cell lines assessed: SK-Mel-2, SK-Mel-5, VMM12, SK-N-
MC, HepG2 and K562 (data not shown). Since SK-Mel-28 cells have
been well-characterized in terms of their cellular Fe uptake mecha-
nisms [36,38,39,44,45], these cells were typically used for all subse-
quent characterization experiments.
3.3. Ascorbate-stimulates 59Fe uptake from 59Fe2-Tf in a time- and
concentration-dependent manner and increases the Vmax of
59Fe uptake
The stimulatory effect of ascorbate on 59Fe uptake from Tf contin-
ued for at least 24 h (Fig. 2A). Moreover, ascorbate caused a signiﬁ-
cant (p b 0.001) increase in 59Fe uptake after only 30 min incubation
with 59Fe2-Tf (Fig. 2B), indicating that stimulation occurred over rela-
tively short 59Fe uptake periods. Pre-incubation of SK-Mel-28 cells
with ascorbate from 5 to 60 min/37 °C, followed bywashing to remove
extracellular ascorbate,was sufﬁcient in a subsequent 3 h/37 °C incuba-
tion to elicit full stimulation of 59Fe uptake from 59Fe2-Tf (Supp. Fig. 1A).
Furthermore, ascorbate at concentrations from 10 to 500 μM had no
more stimulatory effect on 59Fe uptake than that observed at 10 μM
(Supp. Fig. 1B; 59Fe2-Tf incubation time: 2 h). However, to approximate
plasma ascorbate concentrations in healthy humans [43,46], a concen-
tration of 50 μM ascorbate was used in all subsequent studies.
We next assessed the dependence of ascorbate-stimulated 59Fe up-
take on the concentration of 59Fe2-Tf (0.125–12.5 μM; Fig. 2C). Internal-
ized 59Fe uptake was then determined and the results analyzed by
non-linear regression analysis (Fig. 2C). Interestingly, ascorbate signiﬁ-
cantly (p b 0.001) increased the Vmax of 59Fe uptake (from 9.2 ± 0.16
to 13.0 ± 0.29 × 106 atoms 59Fe/cell/h; please note the different units
used for the y-axis in Fig. 2C). As typical serum Fe2-Tf concentrations
are 20–30 μM [21], and that ascorbate-stimulated 59Fe uptake
occurred maximally at a 59Fe2-Tf concentration of 0.75–2 μM
Table 1
Intracellular ascorbate levels in SK-Mel-28 cells before and after incubation with ascorbate or DHA at the indicated concentrations and for the indicated times. Results are mean±
SD (3 experiments).
Intracellular ascorbate, pmol × (106 cells)−1
Cell line (A) No
treatment
(B) Incubation with ascorbate
(50 μM) for 30 min/37 °C
(C) Incubation with ascorbate
(50 μM) for 3 h/37 °C
(D) Incubation with DHA
(50 μM) for 30 min/37 °C
SK-Mel-28 0 ± 1.0 202 ± 15***(vs A) 375 ± 18***(vs B) 534 ± 19***(vs C)
*** pb0.001.
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physiologically relevant.3.4. Ascorbate and Fe2-Tf increase ferritin levels
We next examined whether ascorbate-stimulated 59Fe uptake corre-
lated with alterations TfR1 and ferritin levels. These proteins were exam-
ined as their expression levels are post-transcriptionally controlled in
an Fe-dependent manner via the iron-regulatory protein (IRP)-iron-
responsive element (IRE) system [47,48]. As a consequence, an increase
in cytosolic Fe typically decreases TfR1 synthesiswhile it increases ferritin
synthesis [47,49].
Control and ascorbate-treated SK-Mel-28 cells were incubated
with non-radioisotopic Fe2-Tf (0.75 μM) for 0–24 h (Fig. 3A). The
levels of TfR1, FTH1 and FTL were thenmonitored by western blotting.
As demonstrated in Fig. 2A, although ascorbate linearly stimulated
59Fe uptake over 24 h (Fig. 2A), ascorbate signiﬁcantly (p b 0.01)
down-regulated TfR1 protein by 8 h (Fig. 3A). In contrast, in the ab-
sence of ascorbate, signiﬁcant (p b 0.001) down-regulation of TfR1
only occurred by 24 h (Fig. 3A). Thus, TfR1 protein is more acutely
down-regulated by Fe2-Tf in the presence of ascorbate. Conversely,
FTH1 and FTL protein levels increased at a signiﬁcantly (p b 0.001)
greater rate over 24 h in ascorbate-treated compared to control cells,
with a signiﬁcant (p b 0.001) increase being evident by 3 h (Fig. 3A,
B). Importantly, ascorbate and Fe2-Tf synergistically increased
up-regulation of FTL by 3 h compared to Fe2-Tf or ascorbate alone
(Fig. 3B), which was probably due to increased Fe uptake. Similar re-
sults were found for FTH1 (data not shown). These results areFig. 1. IncubationofhumanmelanomaSK-Mel-28 cellswithascorbate increases internalized
59Fe uptake from 59Fe2-Tf. Cells were pre-incubated with or without ascorbate (50 μM) for
30 min/37 °C before the addition of 59Fe2-Tf ([Tf] = 0.75 μM; [Fe] = 1.5 μM) to the same
medium for 3 h/37 °C. After this incubation, the cell mono-layers were washed on ice and
incubated with Pronase (1 mg/mL) for 30 min/4 °C to obtain the internalized and cell-
membrane fractions. Results are mean + SD (3 experiments).consistent with reports documenting increased de novo synthesis of
ferritin in cells exposed to a combination of ascorbate and Fe [50–52].3.5. An increase in ferritin does not explain ascorbate-stimulated 59Fe
uptake from Tf
The ascorbate/Fe2-Tf-dependent increase in ferritin levels observed
here is probably a consequence, rather than a cause, of ascorbate-
stimulated Fe uptake. Indeed, when cells are presented with low-Mr
Fe, ascorbate enhances ferritin expression by an IRP1/cytosolic
aconitase “switch” mechanism [51]. Thus, we assessed the effects of:
(i) the protein synthesis inhibitor, cycloheximide (20 or 100 μM;
CHX) [53], which abrogates global protein synthesis in SK-Mel-28
cells [53]; or (ii) the cytosolic aconitase inhibitor, oxalomalate (1 or
5 mM) [54], which abolishes aconitase activity of the Fe–sulfur cluster
form of IRP1 [54]. Neither compound signiﬁcantly affected 59Fe uptake
(Supp. Fig. 2).
As ascorbate can inhibit ferritin autophagy [55], and ferritin can
also be degraded by the proteasome [56], we examined the effect of
inhibitors of both these pathways on 59Fe uptake (Supp. Fig. 2). Treat-
ment of cells with inhibitors of autophagy (3-methyladenine; 5 mM)
or the proteasome (MG-132; 10 μM)-conditions previously shown to
inhibit the respective degradative pathways [56] – did not affect 59Fe
uptake (Supp. Fig. 2).
Therefore, our data indicate that ascorbate does not stimulate
Tf-dependent 59Fe uptake by increasing ferritin levels or by increasing
cytosolic aconitase activity.3.6. Incubation of cells with ascorbate and 59Fe2-Tf increased loading of
ferritin with 59Fe
To determine whether ascorbate stimulated Fe-loading of ferritin,
control and ascorbate-treated SK-Mel-28 cells were incubated
with 59Fe2-Tf (0.75 μM) for 0.5–24 h (Fig. 4). The location of the ferritin
band was determined as described in the Materials and methods
section (Supp. Fig. 3A) [41,53]. While incubating cells with 59Fe2-Tf
caused a time-dependent increase in 59Fe-ferritin, which contained the
majority of detectable cellular 59Fe, ascorbate signiﬁcantly (p b 0.001)
increased this by ~2–3 fold at 3, 8 and 24 h (Fig. 4).
Additionally, a putative low-Mr 59Fe pool was identiﬁed in both
control and ascorbate-treated cell extracts (Fig. 4; see Materials and
methods section), although the latter was always signiﬁcantly lower
than the former (data not shown). This pool was veriﬁed as “low-Mr”
by its abolishment by a 1 h/4 °C incubation of native cell extracts with
DFO (100 μM; Supp. Fig. 3B).
It should be noted that the apparent absence of the 59Fe-Tf band
in the 59Fe autoradiograms presented in Fig. 4 and Supp. Fig. 3 is most
likely due to their far lower intensity relative to the 59Fe-ferritin
and low-Mr 59Fe bands. Indeed, as Tf rapidly donates its Fe to cells,
there is only a relatively low steady-state level of 59Fe-Tf in cells. Fur-
ther, as 59Fe-Tf does not accumulate in cells, it can be difﬁcult to detect
in the presence of 59Fe-ferritin, which does accumulate.
Fig. 2. Characterization of ascorbate stimulated iron uptake from 59Fe2-Tf by SK-Mel-28 cells as a function of: (A, B) incubation timewith 59Fe2-Tf, or (C) 59Fe2-Tf concentration. (A, B) Cellswere
pre-incubated with or without ascorbate (50 μM) for 30 min/37 °C before the addition of 59Fe as 59Fe2-Tf ([Tf] = 0.75 μM; [Fe] = 1.5 μM) to the same medium for 1–24 h (A), or 1–60 min
(B) at 37 °C. (C) Cells were pre-incubatedwith orwithout ascorbate as in (A, B) before the addition of 59Fe2-Tf ([Tf] = 0.125–12.5 μM; [Fe] = 0.25–25.0 μM) for a further 3 h/37 °C. For (A–C),
after incubation with 59Fe2-Tf, cells were washed on ice and then incubated with Pronase (1 mg/mL) for 30 min/4 °C to separate the membrane and internalized fractions. Results are
mean + SD (3 experiments).
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cytoplasm in the presence of ascorbate (i) elevates ferritin expression,
probably via an IRP-IRE-regulated increase in de novo ferritin synthesis
[51,57]; and (ii) increases ferritin Fe-loading.
3.7. Ascorbate-stimulated 59Fe uptake from 59Fe2-Tf requires intracellular
ascorbate and not extracellular Fe reduction
Ascorbate-dependent Fe uptake from Fe-citrate requires extracellular
ascorbate and extracellular ferrireduction [4,19,20]. To determine whether
ascorbate-stimulated 59Fe uptake from 59Fe2-Tf occurred by a similar
mechanism, control and ascorbate-treated cells were further incubated
with the cell-impermeant enzyme, ascorbate oxidase (10 U/mL), for a fur-
ther 30 min andduring subsequent incubationwith 59Fe2-Tf or 59Fe-citrate
(Fig. 5). Ascorbate oxidase,which oxidizes ascorbate toDHA,markedly and
signiﬁcantly (p b 0.001) inhibited ascorbate-stimulated 59Fe uptake from
59Fe-citrate ([Fe] = 1.5 μM; Fig. 5A), as previously described [4,19,20],
but did not signiﬁcantly affect 59Fe uptake from 59Fe2-Tf ([Fe] = 1.5 μM;
Fig. 5B). As ascorbate oxidase only oxidizes extracellular ascorbate
[4,7,19], ascorbate-stimulated 59Fe uptake from 59Fe2-Tf does not depend
on the continued presence of extracellular ascorbate.
Next, we examined if the extracellular release of 59Fe from 59Fe2-Tf
was required for ascorbate to stimulate 59Fe uptake from this protein,
as reported for the activation of Tf-dependent Fe uptake by ferric
ammonium citrate [58]. Cells were incubated with the membrane-
impermeant Fe(II) chelators (200 μM), ferene-S, ferrozine [4,20,59], or
bathophenanthroline disulfonate (BPS [45]) for 30 min before addition
of 59Fe2-Tf or 59Fe-citrate to the same medium (Fig. 5).As previously described [4,20], all chelators markedly and signiﬁ-
cantly (p b 0.001) inhibited 59Fe uptake from 59Fe-citrate in the pres-
ence of ascorbate (Fig. 5A). Importantly, and in contrast to 59Fe uptake
from 59Fe-citrate, ferene-S, ferrozine and BPS only reduced 59Fe uptake
from 59Fe2-Tf in the presence of ascorbate by less than 12%, 17% and 36%
(p b 0.01), respectively (Fig. 5B). Similarly, co-incubation of cells with
the avid Fe-binding Tf homologue, apo-lactoferrin (4 μM) almost
abolished ascorbate-stimulated and basal 59Fe uptake from 59Fe-citrate
(Fig. 5A), but only slightly reduced ascorbate-stimulated
59
Fe uptake
from 59Fe2-Tf (i.e., by less than 20% of the 59Fe uptake in the presence
of ascorbate; Fig. 5B).
The observation that all chelators caused some inhibition of
ascorbate-stimulated 59Fe uptake from 59Fe2-Tf (cf. Fig. 5B) is consis-
tent with the ﬁnding that Fe can be labilized by co-incubation with
both strong Fe chelators such as BPS and apo-lactoferrin when a
reductant, such as ascorbate, is present [60].
Therefore, unlike 59Fe uptake from 59Fe citrate, our results suggest
that ascorbate stimulates 59Fe uptake from 59Fe2-Tf by an intracellular
mechanism.
3.8. Studies with ascorbate-scavenging metalloporphyrins indicate the
need for intracellular ascorbate in Tf-59Fe uptake
In order to further evaluate the hypothesis that ascorbate-
stimulated 59Fe uptake from 59Fe2-Tf requires an intracellular pool
of ascorbate, we assessed the ability of the membrane-permeant
metalloporphyrins, MnTMPyP and FeTMPyP, to rapidly catalyze ascor-
bate oxidation [61]. These metalloporphyrins catalyze the oxidation
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of ascorbate auto-oxidation at physiological pH [61]. As these
metalloporphyrins also scavenge superoxide (i.e., MnTMPyP: [62];
FeTMPyP: [63]) and peroxynitrite (i.e., MnTMPyP: [64]; FeTMPyP:
[65]), the membrane-permeant metalloporphyrin, MnTBAP, which
similarly scavenges superoxide [62] and peroxynitrite [61], but is rela-
tively unreactive with ascorbate [61], was used to control for the
non-ascorbate oxidizing activities of MnTMyP and FeTMPyP. All
metalloporphyrins were used at a concentration of 30 μM.
Importantly, when added immediately after pre-incubation of cells
with or without ascorbate, MnTBAP did not affect 59Fe uptake (Fig. 6).
However,MnTMPyP partially inhibited (p b 0.001), whereas FeTMPyP
almost abolished (p b 0.001), only ascorbate-stimulated 59Fe uptake
(Fig. 6). Notably, although both MnTMPyP and FeTMPyP would have
oxidized both intracellular and extracellular ascorbate, the oxidation
of extracellular ascorbate cannot account for the inhibitory action of
these metalloporphyrins, as ascorbate oxidase, which exclusively
and rapidly oxidizes extracellular ascorbate [4,7,19], had no signiﬁcant
effect under the same conditions (Fig. 5B). Thus, these data further
suggest the involvement of intracellular ascorbate in stimulating
59Fe uptake from 59Fe2-Tf.3.9. The reducing ene-diol moiety is required for ascorbate to stimulate
59Fe uptake from 59Fe2-Tf
We next assessed the effects of a range of ascorbate analogues and
degradation products (Fig. 7A) on ascorbate-stimulated 59Fe uptake
from 59Fe2-Tf (Fig. 7B).Fig. 3. Ascorbate potentiates Fe-dependent ferritin expression, but this is not the cause of ascorb
or without ascorbate (50 μM) for 30 min and then Fe2-Tf (0.75 μM) added to this media and t
(i.e., transferrin receptor 1 (TfR1), ferritin heavy chain (FTH1), ferritin light chain (FTL) and the
sitometry of the indicated bands is also shown. (B) The observed increase in FTL expression afte
ascorbate (50 μM) and Fe2-Tf (0.75 μM). Western blots (A and B) are typical results from 3 exThe effect of a change in side-chain stereoisomerism was assessed
with the L-ascorbate epimer, D-isoascorbate (Fig. 7A). Interestingly,
D-isoascorbate can substitute for L-ascorbate in several biologically-
relevant, enzyme-catalyzed reactions and may be imported by cells,
albeit at a lower rate than L-ascorbate [3,66,67]. Interestingly, the stim-
ulation of 59Fe uptake from 59Fe2-Tf by D-isoascorbatewas equivalent to
that of L-ascorbate in both cell lines, indicating that stimulation of 59Fe
uptake by ascorbate is not stereo-speciﬁc (Fig. 7B).
The inﬂuence of changing side chain hydrophobicity was assessed
with L-ascorbate-6-palmitate (Fig. 7A), a highly lipophilic, palmitoylated
L-ascorbate derivative [68], and 5,6-isopropylidene-L-ascorbate, which
is lipophilic and a potential substrate for SVCTs [67]. Like L-ascorbate,
these derivatives have potent reducing activity due to the 2,3-ene-diol
moiety (Fig. 7A) [66,69]. The stimulation of Tf-dependent 59Fe uptake
by L-ascorbate-6-palmitate was very similar to that provided by 5,6-
isopropylidene-L-ascorbate, and in both cases the stimulation was only
marginally lower than that with L-ascorbate (Fig. 7B). Thus, stimulation
of 59Fe uptake does not appear to be sensitive to side chain structure
and/or hydrophobicity.
We then assessed the effect of modiﬁcations to the electron-dense
2,3-ene-diolmoiety (Fig. 7A), which, togetherwith the conjugated struc-
ture of the ﬁve-membered lactone ring, is essential for the one-electron
reducing activity of ascorbate [70]. The importance of this group was
assessed using the two L-ascorbate derivatives, L-ascorbate-2-phosphate
and L-ascorbate-2-sulfate (Fig. 7A), both of which lack reducing activity.
While dephosphorylation of L-ascorbate-2-phosphate by phospha-
tases leads to the slow release of L-ascorbate that can be accumulated
by cells [71], the corresponding sulfate group in L-ascorbate-2-sulfate
is not cleavable bymammalian cells, and correspondingly, thismoleculeate-stimulated 59Fe uptake from transferrin. (A) SK-Mel-28 cells were pre-incubatedwith
he cells then incubated for 0, 3, 8 or 24 h/37 °C. The expression of the indicated proteins
loading control, β-actin) was thenmonitored bywestern blotting. (lower panels) The den-
r a 3 h/37 °C incubation of SK-Mel-28 cells in (A) was dependent on incubation with both
periments, while all graphical data are mean + SD (3 experiments).
Fig. 5. Ascorbate-stimulated 59Fe uptake from 59Fe-citrate (A), but not 59Fe2-Tf (B), requires extracellular ascorbate and extracellular labilization of 59Fe. SK-Mel-28 cells were
pre-incubated with either ascorbate (50 μM) or control medium alone without ascorbate and then either vehicle medium, ascorbate oxidase (10 U/mL), ferene-S (200 μM),
ferrozine (200 μM), apo-lactoferrin (4 μM) or bathophenanthroline disulfonate (BPS; 200 μM) were added, and the cells incubated for a further 30 min/37 °C incubation. Then,
59Fe was added to the same medium as either 59Fe-citrate ([Fe] = 1.5 μM; molar ratio of Fe to citrate = 1:100) (A), or 59Fe2-Tf ([Tf] = 0.75 μM; [Fe] = 1.5 μM) (B), and the
cells were incubated for a further 3 h/37 °C. After this incubation, cells were washed on ice and then incubated with Pronase (1 mg/mL) for 30 min/4 °C to obtain the internalized
and cell-membrane fractions. Results shown are mean + SD (3 experiments).
Fig. 4. Ascorbate-stimulated 59Fe uptake from Fe2-Tf leads to increased loading of ferritin with 59Fe. (top panel) SK-Mel-28 cells were pre-incubated with/without ascorbate (50 μM) for
30 min/37 °C and then 59Fe2-Tf (0.75 μM) was added and the cells incubated for a further 0.5, 3, 8 or 24 h/37 °C incubation. At each time point, cells were harvested and cytoplasmic
extracts were obtained under native conditions at 4 °C and native PAGE 59Fe autoradiography performed. (lower panel) The densitometry of the 59Fe-ferritin and low-Mr 59Fe bands is
also shown, respectively. The native PAGE results are typical results from 3 experiments, while the densitometry in (lower panel) is mean ± SD (3 experiments).
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Fig. 6. Cell-permeant ascorbate-scavenging metalloporphyrins further suggest the in-
volvement of intracellular ascorbate in the stimulation of Tf-dependent 59Fe uptake.
SK-Mel-28 cells were pre-incubated with control medium or ascorbate (50 μM) for
30 min/37 °C. Vehicle medium (MEM + 0.1% DMSO), MnTBAP, MnTMPyP or FeTMPyP
(all at a ﬁnal concentration of 30 μM) were then added to the same medium, and the
cells incubated for an additional 30 min/37 °C. Then, 59Fe2-Tf (0.75 μM) was added and
the cells incubated for a further 3 h/37 °C. After this incubation, cells were washed on
ice and incubated with Pronase (1 mg/mL) for 30 min/4 °C to obtain the internalized
and cell-membrane fractions. Results shown represent internalized 59Fe uptake and are
mean + SD (3 experiments).
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stimulation of cellular 59Fe uptake from 59Fe2-Tf by ascorbate-2-
phosphate was signiﬁcantly (p b 0.001) less than L-ascorbate, it was
still signiﬁcantly (p b 0.01) greater than the ascorbate-free control
(Fig. 7B). In contrast, L-ascorbate-2-sulfate provided no stimulation
(Fig. 7B). Thus, the 2,3-ene-diol moiety is crucial for stimulation of
Tf-dependent 59Fe uptake.
It is important to note that as L-ascorbate-2-phosphate and
L-ascorbate-2-sulfate may not be substrates for SVCTs [67], these an-
alogues may not readily be taken up by cells. Hence, the requirement
for an intact ene-diol in stimulating 59Fe uptake reﬂects a require-
ment for either (i) the reducing activity of ascorbate; and/or (ii) the
SVCT-dependent uptake of ascorbate.
Under standard cell culture conditions, ascorbate is rapidly oxidized to
its two-electron oxidized form, DHA [8]. As expected on the basis of a
requirement for intracellular ascorbate in stimulating Tf-dependent 59Fe
uptake, pre-treatment of cells with DHA, which increased intracellular
ascorbate (Table 1), stimulated 59Fe uptake equivalently to that of
L-ascorbate (Fig. 7B).
As DHA itself is an unstable molecule that undergoes rapid and
irreversible delactonization under physiological and cell culture condi-
tions [1], we examined the following commonDHAdegradation products
for their ability to stimulate Tf-dependent 59Fe uptake: L-(+)-erythrulose,
L-(+)-threonate, L-threose and oxalate [1] (Fig. 7A,B). None of these deg-
radation products had any effect on Tf-dependent 59Fe uptake, which
demonstrates a requirement for the intact vitamin.3.10. Ascorbate-stimulated 59Fe uptake from Tf is not due to a general
increase in cellular reducing capacity
To examine whether a general increase in cellular reducing capacity
could account for ascorbate's effect on 59Fe uptake, SK-Mel-28 cells
were pre-incubated with the following for 24 h/37 °C prior to imple-
mentation of the standard incubation protocol: (i) control medium;
(ii) the membrane-permeant GSH precursor, N-acetylcysteine (NAC;
5 mM) [73], which increases cell GSH in SK-Mel-28 cells [74]; or
(iii) theγ-glutamylcysteine synthetase inhibitor, buthionine sulfoximine(BSO; 10 μM), which markedly attenuates GSH levels in these cells
[75,76]. The results (Fig. 7C) show that modulating cellular GSH had no
signiﬁcant effect on 59Fe uptake (Fig. 7C). Thus, the stimulatory effect
of ascorbate on 59Fe uptake cannot be attributed to a general increase
in cellular reducing capacity.
Next, we assessed whether ascorbate speciﬁcally caused an in-
crease in cellular NADPH levels (Fig. 7D). This was important to assess
as NADPH is thought to be the major electron donor for the
endosomal ferrireductase, Steap3, which contributes to Fe uptake
from Tf in some cells [30] (see also Section 3.11). Interestingly, while
ascorbate had no effect on total NADP levels (i.e., NADP+ + NADPH),
incubation with ascorbate signiﬁcantly (p b 0.001) lowered NADPH
levels (Fig. 7D). The latter is probably due to the requirement
for NADPH in maintaining intracellular ascorbate [1]. There-
fore, the ability of ascorbate to stimulate Tf-dependent Fe up-
take cannot be explained by an increase in cellular NADPH
levels.3.11. Ascorbate-stimulated 59Fe uptake from 59Fe2-Tf is not caused by
either changes in levels of TfR1/2 or Steap3, or changes in cellular 125I-Tf
uptake
Next, we assessed whether the stimulation of Tf-dependent 59Fe
uptake by ascorbate was due to alterations in Tf binding to cells, Tf
uptake and/or Tf cycling. First, using the standard incubation proto-
col, we conﬁrmed that ascorbate, with or without Fe2-Tf, had no effect
on TfR1 expression within 3 h, despite there being a marked increase
in 59Fe uptake in the presence of ascorbate over this period (Fig. 8A;
cf. TfR1 expression in Fig. 3A). Additionally, when cells were incubat-
ed with ascorbate and Fe2-Tf as described in Fig. 3A (see Section 3.4),
there was no signiﬁcant change in TfR2 or Steap3 protein levels
over 0–24 h compared to the relevant controls (Supp. Fig. 4). Thus,
at least in SK-Mel-28 cells, ascorbate does not appear to stimulate
Tf-dependent 59Fe uptake by modulating the levels of these proteins.
It should be noted that although there was some trend towards a
decrease in TfR2 levels in the presence of both ascorbate and Fe2-Tf,
this was not found to be signiﬁcant (Supp. Fig. 4). This is consistent
with the observation that unlike TfR1, TfR2 expression does not ap-
pear to be Fe-regulated [77]. Moreover, although TfR2 protein can
be stabilized by the addition of Fe2-Tf in cells of hepatic origin
[78,79], we did not observe this effect in SK-Mel-28 cells (Supp. Fig.
4). This may be due to the following observations: (i) the stabilization
of TfR2 by Fe2-Tf appears to be speciﬁc to cells of hepatic origin
[78,79] (e.g., endogenous TfR2 is not regulated by Fe2-Tf in K562
cells [79]); and (ii) while our experiments employed a relatively
low Fe2-Tf concentration of 0.75 μM, the stabilization of TfR2 by
Fe2-Tf in HepG2 cells was found to be most pronounced at markedly
higher Fe2-Tf concentrations (i.e., 2.5–25 μM) [78].
Next, we assessed if ascorbate affected the number and/or afﬁnity of
Tf-binding sites at the cell surface (see Materials and methods section).
The apparent dissociation constants and total number of cell-surface
Tf-binding sites were determined using non-linear regression analysis
(Fig. 8B). Our data clearly demonstrate that ascorbate did not signiﬁ-
cantly affect the afﬁnity of Fe2\125I-Tf-binding, or the total number of
speciﬁc cell-surface Tf-binding sites [control = 35,800 ± 1500/cell
(n = 6); ascorbate-treated = 37,100 ± 1800/cell (n = 6)].
We then compared the effect of ascorbate on the relative distribu-
tions of 59Fe and 125I-Tf when SK-Mel-28 cells were co-incubated with
doubly-labeled 59Fe2\125I-Tf (0.75 μM). While pre-incubation of cells
with ascorbate followed by incubation with 59Fe2\125I-Tf (0.75 μM)
resulted in signiﬁcantly (p b 0.001) more 59Fe uptake into the internal-
ized compartment (Fig. 8C), ascorbate did not signiﬁcantly affect 125I-Tf
uptake into either the internalized or cell-membrane compartment
(Fig. 8D). Therefore, ascorbate-stimulated 59Fe uptake from 59Fe2-Tf is
not due to up-regulation of TfRs or increased Tf uptake.
Fig. 7. The reducing ene-diol moiety of ascorbate is necessary for stimulation of 59Fe uptake from 59Fe2-Tf (A,B) and the effect of ascorbate is not due to a general increase in cellular
reducing capacity (C,D). (A) Line drawings of the structures of the ascorbate analogues and degradation products assessed. (B) In these studies, SK-Mel-28 cells were pre-incubated
with or without ascorbate or its analogues/degradation products (50 μM) for 30 min/37 °C before the addition of 59Fe2-Tf ([Tf] = 0.75 μM; [Fe] = 1.5 μM) to the same medium for
a further 3 h/37 °C. (C) Alternatively, SK-Mel-28 cells were treated with either control medium, N-acetylcysteine (NAC; 5 mM) or buthionine sulfoximine (BSO; 10 μM) for 24 h/
37 °C, following which cells were washed and re-incubated in fresh medium with/without ascorbate (50 μM) for 30 min, followed by the addition of 59Fe2-Tf as in (B) to the same
medium. In both (B) and (C), following incubation with 59Fe2-Tf, cells were washed on ice and incubated with Pronase (1 mg/mL) for 30 min/4 °C to obtain the internalized and
cell-membrane fractions. (D) SK-Mel-28 cells were incubated with/without ascorbate (50 μM) as in (B), then Fe2-Tf (0.75 μM) or vehicle were added to the same medium for a
further 3 h/37 °C. Cells were harvested and total NADP (NADP-total) and NADPH levels were determined. Results are mean + SD (3 experiments).
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Fig. 8. Ascorbate-stimulated 59Fe uptake from 59Fe2-Tf is not caused by changes in TfR1 expression or cellular Tf uptake. (A) SK-Mel-28 cells were incubated with or without ascorbate
(50 μM) for 30 min/37 °C, following which non-radioactive Fe2-Tf (0.75 μM), or the equivalent volume of vehicle (i.e., MEM), was co-incubatedwith the cells for a further 3 h/37 °C. The
expression of cellular TfR1 or β-actin (loading control) was then monitored by western blotting (upper panel). The same protocol was used to examine 59Fe uptake except 59Fe2-Tf was
used and a 30 min incubation with Pronase (1 mg/mL/4 °C) was implemented to separate internalized and cell-membrane fractions (lower panel). (B) The total number of SK-Mel-28
cell-surface Tf-receptorswas assessed by pre-incubating cellswith orwithout ascorbate (50 μM) for 30 min/37 °C, then cooling the cells to 4 °C and incubating them for a further 2 h/4 °C
with increasing concentrations of Fe2-125I-Tf (12.5–1000 nM). Cells were then washed on ice and the amount of speciﬁcally bound radioactivity was determined by subtracting the
amount of Fe2-125I-Tf bound in the presence of a 200-fold excess of unlabeled Fe2-Tf. The trend lines shown were obtained by non-linear regression analysis (GraphPad Prism® v. 5.0)
(C, D) SK-Mel-28 cells were pre-incubated in the presence or absence of ascorbate as in (A) followed by a 3 h/37 °C incubation with 59Fe2-125I-Tf (0.75 μM). Cells were washed on ice
and incubation with Pronase (1 mg/mL) for 30 min/4 °C was used to separate the internalized and cell-membrane fractions. Results are mean + SD (3–6 experiments).
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125I-Tf is not caused
by changes in cellular 59Fe or 125I-Tf efﬂux
As ascorbate can suppress cellular 59Fe efﬂux [39], we examined
whether stimulation of 59Fe uptake by ascorbate was due to changes
in 59Fe efﬂux (see Materials and methods section). Consistent with our
previous observations [39], ascorbate caused a slight, yet signiﬁcant
(p b 0.01), inhibition of 59Fe efﬂux (Supp. Fig. 5A). The extent of this
inhibition was equivalent to only ~5% (i.e., 4 ± 1 pmol 59Fe/106 cells)
of internalized 59Fe (Supp. Fig. 5A). In contrast, ascorbate signiﬁcantly
(p b 0.001) stimulated transferrin 59Fe uptake by 40–50 pmol 59Fe/106
cells (Fig. 1; cf. Supp. Fig. 5A). Clearly, the small yet signiﬁcant inhibitory
effect of ascorbate on cellular 59Fe efﬂux can only account for atmost 10%
of ascorbate-stimulated 59Fe uptake from 59Fe2-Tf. Therefore, ≥90% of
the stimulatory effect of ascorbate must be due to enhanced internaliza-
tion of Fe.
Additionally, ascorbate hadno signiﬁcant effect on the extent of 125I-Tf
release into the overlying medium over 3 h/37 °C (Supp. Fig. 5B) or over
shorter time periods of 5–30 min (see Materials and methods section;Supp. Fig. 5C). Therefore, the stimulatory effect of ascorbate on 59Fe up-
take is not due to changes in the rate of 125I-Tf or 59Fe release from cells.
3.13. Ascorbate-stimulated 59Fe uptake requires the cellular expression of
functional TfRs
To determine if ascorbate-stimulated 59Fe uptake from 59Fe2-Tf
required the presence of functional TfRs, we assessed the effect of ascor-
bate on cellular 59Fe and 125I-Tf uptake from 59Fe2-125I-Tf using a select
set of variant CHO cell lines that include TRVb, which does not express
functional endogenous TfRs and is unable to import Fe that is bound to
Tf [32]. In addition, we used TRVb cells that had been transfected to ex-
press either human TfR1 (TRVb/TfR1) [32] or FLAG-tagged human TfR2
(TRVb/TfR2) [33,34,77]. As an additional control, all results were com-
pared to the corresponding levels of 59Fe and 125I-Tf uptake by G418-
resistant TRVb/Neo cells (see Materials and methods section) [34].
Importantly, neither TRVb nor TRVb/Neo cells expressed any detect-
able TfR1 or TfR2, whereas TfR1 and TfR2 were readily detectable in
TRVb/TfR1 and TRVb/TfR2 cells, respectively (Fig. 9A). All cells expressing
Fig. 9. Ascorbate-stimulated 59Fe uptake requires the expression of functional TfRs.
(A) Whole-cell lysates were obtained and the solubilized proteins separated by SDS-PAGE
and the expression of TfR1, TfR2 or β-actin (loading control) was assessed by western
blotting for the following variant Chinese Hamster Ovary (CHO) cells: TRVb (variant CHO
cells devoid of endogenous TfRs; TRVb), or G418/neomycin-resistant TRVb cells transfected
with either pcDNA3-FLAG (TRVb/Neo), human TfR1 (TRVb/TfR1) or FLAG-tagged human
TfR2 (TRVb/TfR2). (B,C) Cells were pre-incubated with/without ascorbate (50 μM) for
30 min/37 °C before the addition of vehicle medium, ascorbate oxidase (Asc Ox; 10 U/mL)
or FeTMPyP (30 μM) to the same medium for a further 30 min/37 °C. Then, 59Fe2\125I-Tf
(0.75 μM) was added to the same medium and cells were incubated for a further
3 h/37 °C. After this incubation, cells were washed on ice and then incubated with
Pronase (1 mg/mL) for 30 min/4 °C to obtain the internalized and cell-membrane
fractions. Results shown are mean + SD (3 experiments).
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internalized 59Fe and 125I-Tf from 59Fe2\125I-Tf (0.75 μM) than TRVb or
TRVb/Neo cells (Fig. 9B,C). Indeed, the latter two cell lines accumulatednegligible levels of 59Fe under these conditions (Fig. 9B). Moreover,
these cells also accumulated very low levels of 125I-Tf compared to the
TfR-expressing cells (Fig. 9C). The TRVb/TfR1 cells accumulated the
highest levels of internalized 59Fe and 125I-Tf (Fig. 9B,C), which is consis-
tent with the apparent primary function of TfR1 in Tf-dependent Fe
uptake [80]. Interestingly, TRVb/TfR2 cells accumulated substantially
lower levels of both radiolabels, albeit at levelsmarkedly and signiﬁcantly
(p b 0.01) higher than that of the TRVb or TRVb/Neo cells (Fig. 9B,C).
Although the major function of TfR2 appears to be as a regulator of the
expression of the hormone of Fe metabolism, hepcidin [49], TfR2 may
also play some role in Tf-dependent Fe uptake [34]. Indeed, the heterolo-
gous expression of human TfR2 in TRVb cells has previously been shown
to promote Tf-dependent 59Fe uptake in an analogous manner to TfR1
under certain conditions [34].
Ascorbate signiﬁcantly (p b 0.001) stimulated the uptake of 59Fe, but
not 125I-Tf, from 59Fe-125I-Tf exclusively in TRVb/TfR1 and TRVb/TfR2
cells (Fig. 9B,C). Notably, and consistent with our previous data (Figs. 5
and 6), the ascorbate-enhanced 59Fe uptake in TfR1-expressing cells
was insensitive to ascorbate oxidase, yet sensitive to the membrane-
permeant ascorbate-oxidizing metalloporphyrin, FeTMPyP (Fig. 9B).
Further, ascorbate had no effect on 59Fe or 125I-Tf uptake by cells
not expressing TfRs (i.e., TRVb or TRVb/Neo cells; Fig. 9B,C). The
observation that ascorbate also enhanced Tf-dependent 59Fe uptake
in TRVb/TfR2 cells indicates TfR2 is sufﬁcient for ascorbate to stimu-
late Tf-dependent 59Fe uptake from Tf. Therefore, the expression
of functional cellular TfRs is necessary for ascorbate-stimulated
Tf-dependent 59Fe uptake to occur.
It should be noted here that, although the human TfR1 cDNA (viz.,
“pCD-TR1”) used by McGraw et al. [32] to create CHO-TRVb/TfR1 cells
contains IREs in the 3′-untranslated region [81], the expression of
human TfR1 by these cells was not affected by ascorbate over the 3 h
interval, as shown by the equivalent 125I-Tf uptake by control and
ascorbate-treated cells (Fig. 9C). Thus, a change in human TfR1
expression cannot account for the stimulatory effect of ascorbate
on Tf-dependent 59Fe uptake in CHO-TRVb/TfR1 cells.3.14. Ascorbate-stimulated Tf-dependent 59Fe uptake requires endocytosis
and intravesicular acidiﬁcation
As the major route of Tf-dependent Fe uptake occurs by the
receptor-mediated endocytic internalization of the Fe2-Tf complex
[21,22], this process is likely to be required for the stimulatory effect
of ascorbate on 59Fe uptake to occur.
First, to examine the involvement of endocytosis in Tf-dependent 59Fe
uptake by control and ascorbate-treated cells, we assessed the effect of
the general inhibitor of endocytosis, phenylglyoxal [45,82]. Phenylglyoxal
(5 mM) inhibits both 59Fe and 59I-Tf uptake from the endocytic internal-
ization of 59Fe2-Tf by SK-Mel-28 cells [45]. In the present study, after
incubation of SK-Mel-28 cells with or without ascorbate, phenylglyoxal
(5 mM) [45] was added to the same medium for a further 30 min/37 °C
before addition of 59Fe2-Tf. In these experiments, phenylglyoxal reduced
both control and ascorbate-stimulated 59Fe uptake from 59Fe2-Tf to
~5% of the vehicle-treated cells (Fig. 10). These data suggest endocytosis
of the TfR1-59Fe2-Tf complex is required for ascorbate-stimulated
Tf-dependent 59Fe uptake.
Next, we assessed the effect on Tf-dependent 59Fe uptake of
the lysosomotropic agents, chloroquine and NH4Cl [83]. These
chemicals cause alkalinization of normally acidiﬁed intracellular vesi-
cles (e.g., endosomes and lysosomes [83]) [84]. As endosomal acidiﬁca-
tion is required for the release of Fe from Fe2-Tf within the endosome
[21,84,85], these agents inhibit Tf-dependent Fe uptake [21,45,84].
The results presented in Fig. 10 clearly show that both chloroquine
(0.5 mM) and NH4Cl (5 mM) markedly and signiﬁcantly (p b 0.001)
inhibited Tf-dependent 59Fe uptake in the presence or absence of
ascorbate.
Fig. 10. Ascorbate-stimulated Tf-dependent 59Fe uptake requires endocytosis and intra-
vesicular acidiﬁcation. SK-Mel-28 cells were pre-incubated with/without ascorbate
(50 μM) for 30 min/37 °C, then either: chloroquine (0.5 mM), NH4Cl (5 mM), baﬁlomycin
A1 (170 nM) or phenylglyoxal (5 mM) were added and the incubation continued for
30 min/37 °C. Then 59Fe2-Tf (0.75 μM)was added to the samemedium and the cells incu-
bated for a further 3 h/37 °C. After this incubation, the cellmono-layerswerewashed on ice
and then incubated with Pronase (1 mg/mL) for 30 min/4 °C to separate the internalized
and cell-membrane fractions. Results shown represent internalized 59Fe uptake and are
mean + SD (3 experiments).
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somes and lysosomes at the expense of ATP [86]. The inhibition of
V-ATPase by baﬁlomycin A1 (150–250 nM) also causes endosomal al-
kalinization that inhibits Tf-dependent 59Fe uptake [87,88]. Similarly to
the lysosomotropic agents, baﬁlomycin A1 (170 nM) signiﬁcantly
(p b 0.001) inhibited Tf-dependent 59Fe uptake (Fig. 10). Interestingly,
in the presence of chloroquine, NH4Cl and baﬁlomycin A1, ascorbate still
stimulated 59Fe uptake by approximately 1.5–2-fold of the respective
control value (Fig. 10). Thus, intravesicular alkalinization does not total-
ly abolish ascorbate-stimulated 59Fe uptake from 59Fe2-Tf, which may
be due to residual 59Fe uptake under these conditions.
4. Discussion
4.1. A novel role for ascorbate in enhancing Fe uptake from Fe-Tf
For theﬁrst time,we have demonstrated that ascorbatemarkedly en-
hances Fe uptake from the major plasma Fe donor, Fe-Tf, in human cells.
This is an important ﬁnding, as ascorbate is a ubiquitous and normally
abundant cellular reductant in vivo, yet it is absent under standard cell
culture conditions [8]. Signiﬁcantly, typical physiological plasma
ascorbate concentrations enhanced 59Fe uptake by up to 1.5–2-fold
from 59Fe2-Tf, which was accompanied by a corresponding increase
in cellular ferritin expression and ferritin-59Fe loading. Although ascor-
bate can increase ferritin either by promoting de novo synthesis [51] or
by inhibiting ferritin autophagy [55], we demonstrated that none of
these processes were responsible for ascorbate's ability to stimulate
Tf-dependent 59Fe uptake. Indeed, these results support the general
notion that ferritin does not contribute to Tf-dependent Fe uptake
per se, although it serves as the major Fe storage depot for nascently
internalized Fe.
4.2. The molecular mechanism involved in ascorbate-stimulated Fe
uptake from Fe2-Tf
To further dissect the ascorbate's mechanism-of-action, we ﬁrst
adopted a comparative approach to determine key differences between
the ascorbate-stimulated uptake from Fe-citrate and Fe2-Tf. We deter-
mined that, unlike 59Fe-citrate [4,19,20], the uptake of 59Fe from 59Fe2-Tfwas largely independent of: (i) the reductive action of extracellular ascor-
bate; and (ii) the extracellular labilization of Fe from Fe2-Tf. In fact, the re-
sults of our experiments with membrane-impermeant (e.g., ascorbate
oxidase) andmembrane-permeant (e.g., FeTMPyP) ascorbate-oxidizing re-
agents strongly suggest that ascorbate acts intracellularly to enhance
Tf-dependent Fe uptake.
Consistent with these ﬁndings, and with the fact that most biolog-
ical activities of ascorbate are mediated by the molecule's reducing
activity [1,70], our results demonstrated that the reducing ene-diol
moiety of ascorbate was required for stimulation of Fe uptake. Impor-
tantly, we also showed that this was not due to a general increase in
cellular reducing capacity in the presence of ascorbate (Fig. 7C), or to
a speciﬁc increase in NADPH. In fact, ascorbate decreased cellular
NADPH (Fig. 7D). Taken together, our results suggest that ascorbate
enhances Tf-dependent 59Fe uptake in a manner dependent on this
molecule.
Intriguingly, while ascorbate did not affect the cellular ﬂux of Tf,
another important ﬁnding was that the expression of human TfRs 1
or 2 in CHO-TRVb cells was necessary for the stimulatory effect of
ascorbate (Fig. 9B). We also showed that this stimulation by ascorbate
was probably mediated by intracellular ascorbate and was not the
result of a change in TfR1 or 2 expression. Our observation that ascor-
bate stimulated Fe uptake in a TfR2-dependentmanner lends some sup-
port to the notion that, in addition to acting as a regulator of hepcidin
production and systemic Fe homeostasis [89], TfR2 may contribute to
the cellular acquisition of Fe from Fe-Tf [34,90]. However, any direct
role for TfR2 in Tf-dependent Fe uptake is likely to be minor in compar-
ison to TfR1 [91,92].
Finally, using an array of well-characterized inhibitors of endocy-
tosis or endosome acidiﬁcation, we demonstrated that endocytosis
and intracellular vesicle acidiﬁcation were important for the mecha-
nism by which ascorbate enhances Tf-dependent Fe uptake
(Fig. 10). Speciﬁcally, endocytosis was necessary for stimulation to
occur, while blockade of intracellular vesicle acidiﬁcation inhibited
both control and ascorbate-stimulated 59Fe uptake similarly, al-
though the relative stimulation provided by ascorbate was not affect-
ed (Fig. 10). Together, these results demonstrate that: (i) endocytosis
is essential for ascorbate to stimulate Tf-dependent Fe uptake; and
(ii) intracellular vesicle acidiﬁcation facilitates both control and
ascorbate-stimulated Fe uptake from Fe2-Tf equally. These observa-
tions show that ascorbate acts to enhance Tf-dependent Fe uptake
downstream of an endocytosis event, which is further enhanced by in-
tracellular vesicle acidiﬁcation.
Taken together, our results indicate that ascorbate acts intracellu-
larly via a reductive mechanism to enhance Tf-dependent Fe delivery
of Fe to cells, which occurs subsequent to the TfR-dependent endocy-
tosis of Fe2-Tf complexes (Fig. 11). Considering the mechanistic
insights provided herein, and the observation by others that ascorbate
promotes mobilization of 59Fe from isolated Tf-containing endosomes
[29,93], we propose a model for ascorbate's activity in which ascorbate
enhances intra-endosomal ferrireduction and, consequently, Fe mobili-
zation from the Tf-containing endosome (Fig. 11). As suggested by stud-
ies with isolated endosomes containing Tf, this could occur by direct
uptake of ascorbate into the endosomal vesicle followed by chemical
ferrireduction [94], and/or by provision of reducing equivalents from
ascorbate to an endosomal ferrireductase [29,93]. As the only conﬁrmed
ferrireductase of the Tf-to-cell Fe uptake cycle is Steap3, which appears
to be most active in this role in erythroid cells [30], the possibility that
ascorbate stimulates Steap3 activity, either directly or indirectly, should
now be examined. However, our ﬁndings that ascorbate did not
increase cellular NADPH (Fig. 7D), a putative electron source for Steap3's
ferrireductase activity [30], or increase Steap3 expression (Supp. Fig. 4),
suggest that ascorbate does not act via Steap3 to enhance Tf-dependent
Fe uptake. Therefore, the possibility that other as-yet-to-be-identiﬁed
endosomal ferrireductases may utilize ascorbate as an electron source
must also be considered.
Fig. 11. Model for the action of ascorbate in stimulating cellular iron (Fe) uptake from transferrin (Tf). (A) Under control conditions, Fe2-Tf binds to cell surface Tf receptors (TfR) and is
internalized by endocytosis. The endosomes that form become acidiﬁed via the proton-pumping vacuolar-type H+-ATPase (V-ATPase). Acidiﬁcation leads to release of Fe from Tf, while
Fe-free Tf (apo-Tf) remains bound to the TfR. The labilized intra-endosomal Fe3+ is then reduced to Fe2+, probably by a reductase and transported across the endosomalmembrane by the
divalent metal transporter 1 (DMT1) and/or Zip14. The apo-Tf–TfR complex returns to the cell surface, where apo-Tf dissociates at neutral pH. After transport by DMT1/Zip14, Fe initially
enters the labile Fe pool (LIP) and can be stored in ferritin. (B) In contrast, in the presence of ascorbate, the vitamin enhances: (i) Tf-dependent Fe uptake; (ii) ferritin expression; and
(iii) Fe deposition in ferritin. Importantly, the ascorbate-dependent increase in the LIP probably causes increased ferritin synthesis. Our results indicate that ascorbate acts intracellularly
via a reductive mechanism that probably (as indicated by dotted lines) either involves direct import of ascorbate into the Tf cycle endosome and direct or chemical ferrireduction and/or
provision of electrons to an endosomal ferrireductase to enhance Tf-dependent Fe delivery of Fe to cells.
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Tf-dependent Fe uptake is signiﬁcant for the following reasons: (i) thema-
jority of in vitro studies on Tf-dependent Fe uptake have been with
performed with ascorbate-depleted cells; and (ii) severe ascorbate-
deﬁciency in humans (i.e., scurvy), as well as experimentally-induced
ascorbate deﬁciency in guinea pigs, causes an “anemia of scurvy”
[11,12]. The observation that ascorbate enhances Fe uptake from Fe2-Tf
in all human cells examined suggests that the many previous studies
on cellular Fe metabolism and Tf-dependent Fe uptake may have
overlooked the involvement of this important reductant. Moreover, the
ability of ascorbate to enhance Fe uptake from Fe2-Tf, which is thought
to be the major donor of Fe to the erythropoietic compartment [22],
could explain the metabolic defect that contributes to ascorbate-
deﬁciency-induced anemia.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbamcr.2013.02.010.
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